Table 3.
Solicited adverse events - summary table
| Subjects with 1 or more AEs: | Ad26/MVA | Ad26/Ad26 + gp140 | Placebo |
|---|---|---|---|
| Analysis set: Full analysis set | 10 | 9 | 6 |
| Post-Any Dose | 10 | 9 | 6 |
| Solicited AEs | 10 (100.0%) | 9 (100.0%) | 5 (83.3%) |
| Solicited AEs of grade 3 | 2 (20.0%) | 4 (44.4%) | 0 |
| Solicited AEs of grade 4 | 0 | 0 | 0 |
| Solicited local AEs | 9 (90.0%) | 8 (88.9%) | 4 (66.7%) |
| Solicited local AEs of grade 3 | 1 (10.0%) | 0 | 0 |
| Solicited local AEs of grade 4 | 0 | 0 | 0 |
| Solicited systemic AEs | 9 (90.0%) | 8 (88.9%) | 4 (66.7%) |
| Solicited systemic AEs of grade 3 | 1 (10.0%) | 4 (44.4%) | 0 |
| Solicited systemic AEs of grade 4 | 0 | 0 | 0 |
| Solicited systemic AE that is thought to be related to study vaccine | 9 (90.0%) | 8 (88.9%) | 4 (66.7%) |
| Solicited systemic AE of at least grade 3 and that is thought to be related to study vaccine | 1 (10.0%) | 4 (44.4%) | 0 |
Subjects are counted only once for any given event, regardless of the number of times they actually experienced the event. The denominator is the number of subjects with available reactogenicity data after the given dose.
Key: AE adverse event.